Literature DB >> 14707410

Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke.

Geert Sulter1, Jan Willem Elting, Natasha Maurits, Gert Jan Luijckx, Gert Jan Luyckx, Jacques De Keyser.   

Abstract

BACKGROUND: Because elevated body temperature (BT) in acute ischemic stroke is associated with poor outcome, it is currently recommended to maintain normothermia with antipyretics. Whether this can be achieved by the administration of acetylsalicylic acid (ASA) or acetaminophen is uncertain.
METHODS: Over a period of 9 months, patients admitted with acute hemiparetic ischemic stroke were monitored for BT in the first 48 h. When BT rose >37.5 degrees C, patients were treated with either ASA 500 mg intravenously or acetaminophen suppository 1,000 mg. When 6 h later the BT was still or again >37.5 degrees C, patients were further treated with acetaminophen suppository 1,000 mg up to 4 times a day. Primary outcome measure was normothermia (BT </=37.5 degrees C) within respectively 1 and 3 h after intervention. Secondary outcome parameters were any decrease in BT and the mean decrease in BT.
RESULTS: Of a total of 132 patients, 63 (48%) developed a BT >37.5 degrees C. The effects of 43 injections of ASA and 89 administrations of acetaminophen were studied. After 1 h, treatment with acetaminophen produced both significantly more reductions in BT and normothermia (respectively in 60 and 20%) than treatment with ASA (respectively in 37 and 5%). At 3 h, both interventions had a similar effect, with normothermia being achieved in only 37-38%. Fever (>38.0 degrees C) and evidence of an infection were related to unresponsiveness to treatment.
CONCLUSIONS: In the majority of patients with acute ischemic stroke, ASA and acetaminophen are insufficient for reducing an elevated BT to a state of normothermia. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14707410     DOI: 10.1159/000075779

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  10 in total

Review 1.  Fever management in SAH.

Authors:  V Scaravilli; G Tinchero; G Citerio
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

Review 2.  Prophylactic Antibiotic Therapy for Preventing Poststroke Infection.

Authors:  Stefan Schwarz
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

Review 3.  Normothermia and Stroke.

Authors:  Jonathan Marehbian; David M Greer
Journal:  Curr Treat Options Neurol       Date:  2017-01       Impact factor: 3.598

4.  Inferior Vena Cava Thrombosis Related to Hypothermia Catheter: Report of 20 Consecutive Cases.

Authors:  Andres Reccius; Pablo Mercado; Patricio Vargas; Claudio Canals; Jose Montes
Journal:  Neurocrit Care       Date:  2015-08       Impact factor: 3.210

Review 5.  Treatment of fever after stroke: conflicting evidence.

Authors:  Sylwia E Wrotek; Wieslaw E Kozak; David C Hess; Susan C Fagan
Journal:  Pharmacotherapy       Date:  2011-11       Impact factor: 4.705

6.  The impact of hyperthermia and infection on acute ischemic stroke patients in the intensive care unit.

Authors:  Woo-Keun Seo; Sung-Wook Yu; Ji Hyun Kim; Kun-Woo Park; Seong-Beom Koh
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

7.  Ischemic stroke and neuroprotection.

Authors:  Io Onwuekwe; B Ezeala-Adikaibe
Journal:  Ann Med Health Sci Res       Date:  2012-07

8.  Early changes in physiological variables after stroke.

Authors:  Andrew A Wong; Stephen J Read
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383

9.  Temporal profile of body temperature in acute ischemic stroke: relation to stroke severity and outcome.

Authors:  Bartosz Karaszewski; Ralph G R Thomas; Martin S Dennis; Joanna M Wardlaw
Journal:  BMC Neurol       Date:  2012-10-18       Impact factor: 2.474

10.  In Utero Caffeine Exposure Induces Transgenerational Effects on the Adult Heart.

Authors:  Xiefan Fang; Ryan R Poulsen; Scott A Rivkees; Christopher C Wendler
Journal:  Sci Rep       Date:  2016-09-28       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.